{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"14.4","value":"10.2"},{"groupId":"OG001","lowerLimit":"34.8","upperLimit":"46.5","value":"40.6"}]}],"title":"MRD negative rate (10^-4)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"10.3","value":"6.7"},{"groupId":"OG001","lowerLimit":"27.8","upperLimit":"39.0","value":"33.2"}]}],"title":"MRD negative rate (10^-5)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"4.1","value":"1.8"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"17.8","value":"13.3"}]}],"title":"MRD negative rate (10^-6)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"286"}],"units":"Participants"}],"description":"Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \\<5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\\^ minus (-) 4, 10\\^-5, 10\\^-6 threshold.","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"NUMBER","populationDescription":"ITT analysis set included all participants who were randomly assigned to the DRd or Rd group.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of first documented evidence of PD (up to 87.5 months)","title":"Percentage of Participants With Negative Minimal Residual Disease (MRD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}